Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

InvestingPro's Fair Value model identified (NASDAQ:SYRE) as significantly overvalued at $37.65, providing investors with a crucial warning signal. Nearly a year later, this analysis has proven ...

Clinical trials help researchers studying chronic conditions answer important questions about the diseases and their treatment options. However, uncertainty about what to expect and a lack of ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...

Diet plays a pivotal role in influencing autoimmune diseases like multiple sclerosis (MS), inflammatory bowel disease, and ...

Patients with ankylosing spondylitis and IBD exhibit distinct clinical and radiographic features, compared against those without comorbid IBD.

Objectives Primary sclerosing cholangitis (PSC) is a rare chronic disease that presents challenges to both patients and ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...